tbuckley/cabot-search huggingface dataset:
Extensive Bone Metastases in a Patient with Prostatic Adenocarcinoma and Normal Serum Prostate-Specific Antigen and Prostatic Acid Phosphatase
Authors: MAHMUT YUKSEL, T. FIKRET ÇERMIK, MERYEM KAYA, AHMET SALAN, FUNDA USTUN, Y. SAMI SALIHOGLU, ÖMER N. YIGITBASI, ŞAKIR BERKARDA
Journal: Clinical Nuclear Medicine (2001)

YUKSEL, MAHMUT M.D.; ÇERMIK, T. FIKRET M.D.; KAYA, MERYEM M.D.; SALAN, AHMET M.D.; USTUN, FUNDA M.D.; SALIHOGLU, Y. SAMI M.D.; YIGITBASI, ÖMER N. Ph.D.; BERKARDA, ŞAKIR M.D. Author Information
The black to white breast cancer incidence rate crossover.
Authors: WF Anderson, PS Rosenberg, I Jatoi, RM Pfeiffer
Journal: Cancer Research (2009)

Abstract Abstract #2086 Background: Although breast cancer incidence rates are higher among Blacks than Whites prior to age 40 years, the reverse is true after age 40 years. This so-called Black to White ethnic crossover has been described but never systematically studied.&amp;#x2028; Materials and Methods: To further assess the Black to White incidence rate crossover, we obtained data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Invasive female breast cancers were stratified by Black and White race and estrogen receptor (ER) expression. Standard descriptive epidemiology was supplemented with “comparative” age-period-cohort (APC) models.&amp;#x2028; Results:]We observed “qualitative” (reversing or crossing) age-interactions by race, stratified by birth-cohort and adjusted for calendar-period. For example, APC fitted age-at-onset curves were higher among Blacks than Whites prior to age 40 years, and then rates crossed, after which age-specific rates were higher for Whites (p ∼ 0 for difference). In contrast to age-related differences, secular trends were similar for Blacks and Whites (net drifts, p = 0.85 for difference). For all time periods and age groups, ER negative incidence rates were higher among Blacks, whereas ER positive rates were higher among Whites.&amp;#x2028; Conclusion: When viewed as a qualitative (crossing) age-interaction, the Black to White ethnic crossover reflects the reversal of incidence rate ratios for early-onset/poor prognosis and late-onset/good prognosis breast cancer types. Blacks have more early-onset and ER-negative tumors, even after adjustment for calendar-period (screening) and birth-cohort (exposure) effects.&amp;#x2028; &amp;#x2028; Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2086.
OP0160 Characterization of Systemic Lupus Erythematosus Subgroups with Features of Antiphospholipid or Sjögrens's Syndrome Utilizing Affinity Proteomics
Authors: H. Idborg, A. Zandian, J.T. Gustafsson, I. Gunnarsson, E. Svenungsson, P. Nilsson, P.-J. Jakobsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is an autoimmune disease that covers a wide range of phenotypes, from subtle symptoms to life-threatening conditions. The heterogeneous presentation of SLE is a major obstacle in clinical trials and the lack of biomarkers also hampers accurate diagnosis and choice of treatment. <h3>Objectives</h3> In this study we explored biochemical pathways in two suggested subgroups of SLE utilizing affinity proteomics in order to characterize subgroups and identify biomarkers for personalized medicine. <h3>Methods</h3> We have utilized Karolinska SLE cohort consisting of 320 well-characterized SLE patients and 320 individually matched population based controls in a cross-sectional study. SLE subgroups were defined only based on patients9 autoantibody profile: an Antiphospholipid Syndrome-like (APS-like, n=55) and a Sjögren9s Syndrome-like (SS-like, n=58) subgroup. Based on literature and clinical knowledge we have made a targeted selection of 281 proteins targeted by in total 367 antibodies from the Human Protein Atlas. Antibodies were covalently coupled to color-coded magnetic beads. EDTA-plasma samples were labeled with biotin and screened in a 384 bead array format. The read-out was made by adding a streptavidin fluorophore and using suspension bead arrays. <h3>Results</h3> We identified differences in protein profiles comparing APS-like and SS-like SLE subgroups: The top most significantly different proteins were Integrin beta 1 (p=9.8e-8, Log2 fold change=1,5), renin (p=2.7e-5, Log2 fold change=0.5), glutamic-oxaloacetic transaminase 1 (p=2.9e-5, Log2 fold change=0,5) and Apolipoprotein M (p=3.4e-5, Log2 fold change=0,3) that all were increased in SS-like SLE, while Apolipoprotein H (β2-GPI, p=6.6e-5, Log2 fold change=-0,3) were increased in the APS-like subgroup. <h3>Conclusions</h3> The two suggested SLE subgroups were defined exclusively on autoantibody profile as the APS-like and the SS-like subgroups. Our results demonstrate that the two subgroups differ in their protein profiles and that these observations indicate underlying pathogenic differences between SS-like and APS-like SLE. A common etiology of the presence of β2-GPI in both APS and in APS-like SLE is suggested. Therefore, we believe that stratification of SLE patients should be further explored towards personalized medicine. <h3>Disclosure of Interest</h3> None declared
Scintigraphic Detection of Invasive Cutaneous Malignant Melanoma With Tc-99m MIBI
Authors: OMAR ALONSO, MIGUEL MARTINEZ, GRACIELA LAGO, CARLOS BAZZANO, ALI SAADOUN, FERNANDO MUT, LUCIA DELGADO, JOSE ESPASANDIN, EDUARDO TOUYA
Journal: Clinical Nuclear Medicine (1996)

Malignant melanoma is a relatively uncommon cancer of increasing incidence. The authors report on two cases of malignant melanoma lesions (primary and lymph node metastasis) imaged with Tc-99m MIBI. One patient revealed intense accumulation of the radiotracer in a primary skin lesion of the thorax, whereas the other patient showed increased Tc-99m MIBI uptake in a lymph node metastasis of the neck. Tc-99m MIBI imaging could be helpful in the evaluation of patients with suspicious skin lesions and in patients with known cutaneous malignant melanoma, in the investigation of lymph nodal invasion, local recurrence, and metastatic spread.
Abstract 5433: Dietary factors and the risk of esophageal cancer: A population-based cohort study in Korea
Authors: Byung-Ho Nam, Jeongin Bak, Jeongseon Kim
Journal: Cancer Research (2012)

Abstract Objective: To date, there have been few prospective cohort studies that have investigated the association between dietary factors and the risk of esophageal cancer (EC). A large population-based cohort study was conducted to assess the effect of dietary factors on the risk of EC in Korean adults. Methods: The data for this study came from the National Health Insurance Corporation Study (NHICS), Korean Central Cancer Registry. The participants aged 30-80 years were 822,745 Korean men and 368,918 women, cancer-free at baseline in 1996 and 1997, and were followed up to December 31, 2007. The hazard ratio (HR) and 95% confidence interval (CI) of the HR were estimated using the Cox proportional hazards regression model. Results: During the follow-up period, crude incidence rates per 100,000 person-years for EC were 8.1 in overall total population, 11.1 in men, and 1.2 in women. In the total population, the estimated HRs (95% CI) for meat consumption of more than 4 times per week compared with consumption of less than once per week were 1.267 (1.018-1.577) with a p value of 0.0337. In men only groups, the HRs (95% CI) for those who had irregular meal patterns compared with those with regular meal patterns were 1.359 (1.087-1.699) with a p value of 0.0071. Conclusion: The present findings suggest that dietary factors may be associated with the risk of EC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5433. doi:1538-7445.AM2012-5433
Abstract 1566: Inhibition of TGF-β in tumor-draining lymph nodes can enhance the potency of dendritic cell-based vaccine immunotherapy
Authors: Koji Teramoto, Takuya Fujita, Jun Hanaoka, Noriaki Tezuka, Keiichi Kontani
Journal: Cancer Research (2012)

Abstract Transforming growth factor-β (TGF-β), an immunosuppressive cytokine, produced in the tumor microenvironment will flow into tumor-draining lymph nodes where are primary priming sites for generation of anti-tumor immune responses, and play a critical role in suppressing anti-tumor immune responses. We focused on TGF-β-mediated immunosuppression in tumor draining lymph nodes, and examined whether local inhibition of TGF-β there could enhance the potency of dendritic cell (DC) -based vaccine immunotherapy in tumor-bearing mice. C57BL/6 mice bearing Lewis lung carcinoma (LLC1) subcutaneously were vaccinated with DCs loaded with LLC1-derived antigen. In order to inhibit TGF-β in tumor-draining lymph nodes, those mice were administered the plasmid DNA encoding the extracellular domain of TGF-β type II receptor fused to the human IgG heavy chain (TGFR DNA) near the established tumor intramuscularly. As results, the level of TGF-β in tumor-draining lymph nodes was decreased by administrations of TGFR DNA near the established tumor. In tumor-draining lymph nodes, the proliferative activity of FoxP3+ regulatory T cells was eliminated, whereas tumor antigen-specific CD8+ cells producing interferon-α were increased as compared with those in mice administered DC vaccine alone. In spleen, tumor antigen-specific cytotoxic as well as natural killer activity were augmented in mice administered DC vaccine with TGFR DNA. Subsequently, growth of the established tumor was suppressed effectively. In conclusion, inhibition of TGF-β-mediated immunosuppression in tumor-draining lymph nodes can significantly enhance the potency of DC vaccine. This animal model provides for a novel rationale with DC vaccine immunotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1566. doi:1538-7445.AM2012-1566
AB0046 The sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes
Authors: K. Ikuta, Y. Nagaya, T. Terazawa, M. Aoyama, K. Asai, M. Kobayashi, T. Otsuka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Gliostatin/thymidine phosphorylase (GLS) has angiogenic and arthritogenic activities, and GLS production has been observed in the active synovial membranes of rheumatoid arthritis (RA) patients. The human GLS gene promoter contains at least seven consensus binding sites for the DNA binding protein Sp1. <h3>Objectives</h3> We examined whether Sp1 is necessary for GLS production in RA. We also studied the effects of the Sp1 inhibitor mithramycin on GLS production in RA fibroblast-like synoviocytes (FLSs). <h3>Methods</h3> The gene and protein expression of GLS were studied using the quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and an enzyme immunoassay. Intracellular signalling pathway activation was determined by a luciferase assay, a chromatin immunoprecipitation (ChIP) assay and a small interfering RNA (siRNA) transfection. <h3>Results</h3> The luciferase and ChIP assays showed that Sp1 binding sites in the GLS promoter were essential for GLS messenger RNA (mRNA) expression. GLS production was suppressed in FLSs by siRNA against Sp1 transfection. Mithramycin decreased GLS promoter activity, mRNA and protein expression in FLSs. Tumour necrosis factor-α (TNF-α) significantly increased GLS expression in RA FLSs; this effect was reduced by pre-treatment with mithramycin. <h3>Conclusions</h3> Pretreatment of mithramycin and Sp1 silencing resulted in a significant suppression of GLS production in TNF-α-stimulated FLSs compared to controls. GLS gene expression enhanced by TNF-α was partly mediated through Sp1. As physiological concentrations of mithramycin can regulate GLS production in RA, mithramycin is a promising candidate for anti-rheumatic therapy. <h3>Acknowledgements</h3> This research was supported by a Grant-in-Aid for Scientific Research (C)(23592225) from the Japan Society for the Promotion of Science. <h3>Disclosure of Interest</h3> None Declared
GE-33 * A COMPREHENSIVE ASSESSMENT OF VIRAL TRANSCRIPTS IN DNA- AND RNA-SEQ DATASETS FROM HIGH-GRADE GLIOMAS REVEALS NO ASSOCIATION
Authors: M. J. Strong, G. Blanchard, M. Baddoo, C. Morris, C. M. Taylor, M. L. Ware, E. K. Flemington
Journal: Neuro-Oncology (2014)

Glioblastoma multiforme (GBM) is a devastating disease with poor survival rates. Despite years of research, there has been little change in the survival rate or median survival time. HCMV (human cytomegalovirus) was reported in GBM over a decade ago and this finding has the potential to increase our understanding of the disease and it offers a potential tumor specific therapeutic target. Because of this promise, there is a fair amount of time, energy and money being directed towards understanding and utilizing this connection for eventual therapeutic purposes. Despite these ongoing efforts and the time lapsed since the discovery of HCMV in GBM, the association remains controversial. Here we utilized both RNA and DNA sequence data from high-grade gliomas from the Cancer Genome Atlas to assess the veracity of the association between GBM and HCMV (or other infectious agents). Raw sequence reads were aligned to a reference genome containing a human genome (hg19) and a library of virus sequences known to infect humans. Alignments were performed using Spliced Transcripts Alignments to a Reference (STAR). In 56 out of 56 GBM RNA-seq datasets no known viruses were identified. Virome analysis of the DNA-seq datasets demonstrated 40 out of 40 datasets with human herpesvirus 7 ranging from 32 to 10,845 reads. However, upon further analysis, it was determined that these herpesvirus 7 matching reads have low complexity and are consistent with mapping to human telomeric repeats. Therefore, no known viruses were identified at the DNA or RNA levels. This analysis raises the possibility that viruses may not be associated with gliomas as previously reported.
SP0152 What risk am I willing to take for what benefit?
Authors: M.J. Scholte Voshaar
Journal: Annals of the Rheumatic Diseases (2013)

Decisions which previously were taken by the health professional alone are nowadays resulting from a shared decision making process in which patients obtain information from different sources. How patients assess the risks and benefits regarding treatment for their condition, can differ from the assessment of health professionals. Message framing of the treatment regarding benefits and risks and evidence of the effect of the treatment are just a few of the variables that may influence the choice of the patient. Shared decision making can enhance the patients understanding of treatment options and heighten confidence to make that choice, which will improve satisfaction with the chosen treatment. However, anxiety and unfamiliarity with the disease (a lack of, or perhaps even poor information), as well as with the multitude of treatment alternatives, are issues that should not be ignored. The patient perspective on the perception of benefits and risks and the trade-offs between those will be stressed. Personal experiences of situations in which benefit-risk decisions were important (in research as well as in clinical practice), will be highlighted and differences of risks (disease vs. non-disease related risks) as well as the possibility of prevention of risks will be explained. Effective communication regarding benefits and risks is essential for the patient in order to make a balanced choice and obtain better health outcomes. This presentation will assist in understanding the decision making process of patients, who have to face the actual day-to-day consequences of those decisions. <h3>Disclosure of Interest</h3> None Declared
Abstract 806: Upregulation of Krüppel-like Factor 4 (KLF-4) expression as a potential tumor progression gene product in non-Hodgkin's lymphoma
Authors: Mario I. Vega, Miriam Hernandez-Atenógenes, Juan C. Vazquez-Islas, Bernardo Martinez-Miguel, Melisa A. Martinez-Paniagua, Gabriela Antonio-Andres, Clara M. Rivera-Pazos, Altagracia Maldonado-Valenzuela, Otoniel Martinez-Maza, Sara Huerta-Yepez, Benjamin Bonavida
Journal: Cancer Research (2010)

Abstract Krüppel-like factor 4 (KLF-4) is highly expressed in epithelial tissues such as gut and skin. Several studies based on clinical evidence suggest that KLF-4 functions as a tumor suppressor in cancer of colon, bladder, stomach and in leukemia. In contrast, KLF-4 expression is increased in primary breast ductal carcinomas and in oral dermal squamous cell carcinomas, suggesting that KLF-4 is important in tumor development and progression. However, KLF-4 expression in lymphomas has not been investigated. Our preliminary studies have examined KLF-4 expression in lymphoma cell lines and a TMA containing fresh tissues derived from patients with several types of lymphoma. There was a significant higher expression of KLF-4 in Burkitt's lymphoma compared with other lymphomas such as follicular or DLBCL. These findings suggest that KLF-4 may be considered as a new biomarker in Non-Hodgkin's lymphoma (NHL). Further analyses based on the clinical outcome revealed that KLF-4 protein expression was significantly associated with poor patient's survival. The increased KLF-4 expression was associated with an inferior survival duration (P= 0.002). The survival for 12 patients who had a tumor with weak KLF-4 expression and 13 patients with negative KLF-4 expression was significantly longer than the 30 patients with strong KLF-4 expression (P&amp;lt; 0.001). Other variables that affected survival in univariate analyses included stages and completeness of resection were shown to have statistically significant effect on survival (P=0.001), however age or sex did not have a statistically significant effect on survival. These data provide the first clinical and causal evidences that alterations of KLF-4 expression can play a critical role in the development and progression of NHL. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 806.
ASSESSMENT OF PROGNOSIS IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION: A NEW APPROACH TO QUANTITATIVE INTERPRETATION OF EXERCISE THALLIUM-201 SCINTIGRAPHY
Authors: Jamshid Maddahi, Hosen Kiat, Ken Resser, Joe Areeda, Ken Van Train, Todd Kotler, Ishac Cohen, Alan Waxman, Daniel Berman
Journal: Clinical Nuclear Medicine (1987)

Maddahi, Jamshid; Kiat, Hosen; Resser, Ken; Areeda, Joe; Train, Ken Van; Kotler, Todd; Cohen, Ishac; Waxman, Alan; Berman, DanielAuthor Information
520 RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B
Authors: O. Keskin, A. Ormeci, G. Kabacam, F. Akyuz, H. Aniktar, C. Karaca, R. Idilman, S. Kaymakoglu, C. Yurdaydin
Journal: Journal of Hepatology (2012)
Competition in NHS is driving patients towards private providers
Authors: Z. Kmietowicz
Journal: BMJ (2012)

Independent sector treatment centres (ISTCs) have become firmly established as providers of NHS care in England, delivering operations for nearly one in five patients in some specialties, shows an analysis.

The analysis, which set out to map how the choice agenda in England has changed where patients are treated, found that between 2003-4 and 2010-11 the proportion of hip replacement operations carried out at patients’ nearest hospital trust fell from 68% to 54%. By 2010-11 ISTCs were the locations for 17% of these operations.1

Similarly, the proportion of hernia operations carried out at patients’ nearest trusts fell …
Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer
Authors: J. A. Foekens, M. P. Look, H. A. Peters, W. L. J. van Putten, H. Portengen, J. G. M. Klijn
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer Get access John A. Foekens, John A. Foekens Division of Endocrine Oncology, Department of Medical Oncology, Dr. Daniel den Hoed Cancer CenterRotterdam, The Netherlands Correspondence to : John A. Foekens, Ph.D., Dr. Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 AE Rotterdam, The Netherlands. Search for other works by this author on: Oxford Academic PubMed Google Scholar Maxime P. Look, Maxime P. Look Division of Endocrine Oncology, Department of Medical Oncology, Dr. Daniel den Hoed Cancer CenterRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Harry A. Peters, Harry A. Peters Division of Endocrine Oncology, Department of Medical Oncology, Dr. Daniel den Hoed Cancer CenterRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Wim L. J. van Putten, Wim L. J. van Putten Department of Statistics, Dr. Daniel den Hoed Cancer CenterRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Henk Portengen, Henk Portengen Division of Endocrine Oncology, Department of Medical Oncology, Dr. Daniel den Hoed Cancer CenterRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Jan G. M. Klijn Jan G. M. Klijn Division of Endocrine Oncology, Department of Medical Oncology, Dr. Daniel den Hoed Cancer CenterRotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 10, 17 May 1995, Pages 751–756, https://doi.org/10.1093/jnci/87.10.751 Published: 17 May 1995 Article history Received: 15 September 1994 Revision received: 08 March 1995 Accepted: 13 March 1995 Published: 17 May 1995
Decreased Bilateral Frontal Lobe Perfusion in Dementia of Amyotrophic Lateral Sclerosis
Authors: DOUGLAS P. BEALL, DAVID MARTIN, BENNETT B. CHIN
Journal: Clinical Nuclear Medicine (1998)

A 59-year-old woman with amyotrophic lateral sclerosis (ALS) and normal results of brain MRI was evaluated for slowly progressive dementia. A Tc-99m biscate (technetium 99m-biscate ethyl cysteinate dimer) study showed diffuse, regional decreased blood flow in the bilateral frontal lobes. This pattern conforms to the previously described pattern of bilateral decreased frontal lobe perfusion as quantified by O-15 water positron emission tomography and other blood flow tracers such as I-123 iodoamphetamine. This dementia associated with ALS is thought to be related to this pattern of decreased blood flow. MRI may show degeneration of the pyramidal tracts in patients with ALS, but this is an inconsistent finding. Tc-99m ECD brain SPECT may be useful to identify patients with dementia of ALS, thus differentiating this entity from other causes of dementia, such as Alzheimer's disease or multiple-infarct dementia from cerebral vascular disease. Identifying this pattern and establishing this diagnosis may obviate the need for further evaluation of potentially correctable causes of dementia.